β-Hydroxybutyrate enhances malate dehydrogenase 2 β-hydroxybutyrylation to alleviate hepatic steatosis in MASLD.

ABSTRACT: Over the past three decades, the global prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) has rapidly increased, leading to significant economic and clinical burdens. However, aside from resmetirom (Rezdiffra™), an oral thyroid hormone receptor-β agonist, there remains a lack of approved targeted pharmacological treatments for MASLD, emphasizing the need for more optimized therapeutic strategies. Given the limitations in the safety and efficacy of the ketogenic diet, β-hydroxybutyrate (β-OHB) has emerged as a crucial regulator in MASLD treatment, but the precise mechanisms underlying its therapeutic effects remain unclear. This study aims to investigate the therapeutic effects of β-OHB on MASLD mice and elucidate the underlying mechanisms. In this study, we dem

SUBMITTER: Cai J 

PROVIDER: S-EPMC12552210 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature